290 related articles for article (PubMed ID: 12143465)
1. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
Besarab A; Dalton CL
Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
[TBL] [Abstract][Full Text] [Related]
2. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
Easom A
Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
[TBL] [Abstract][Full Text] [Related]
3. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
Dukkipati R; Kalantar-Zadeh K
Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
[TBL] [Abstract][Full Text] [Related]
4. Updating practices in an evolving IV iron and anemia environment: practical solutions.
Amerling R; Easom A; Juergensen P
Nephrol Nurs J; 2007; 34(5):533-41; quiz 542-3. PubMed ID: 18041456
[TBL] [Abstract][Full Text] [Related]
5. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
Peacock E; Lindenfeld SM
ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
[TBL] [Abstract][Full Text] [Related]
6. Caring for the renal failure patient: optimizing iron therapy.
Folkert VW; Javier AM; O'Mara NB
Nephrol Nurs J; 2002 Dec; 29(6):586-93; quiz 594-5. PubMed ID: 12596608
[TBL] [Abstract][Full Text] [Related]
7. Intravenous iron dextran treatment in predialysis patients with chronic renal failure.
Dahdah K; Patrie JT; Bolton WK
Am J Kidney Dis; 2000 Oct; 36(4):775-82. PubMed ID: 11007680
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive vision for intravenous iron therapy.
Coyne DW
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
[TBL] [Abstract][Full Text] [Related]
9. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
10. Impact of inflammation on nutrition, iron status, and erythropoietin responsiveness in ESRD patients.
Bistrian BR; Carey LA
Nephrol Nurs J; 2000 Dec; 27(6):616-22. PubMed ID: 16649343
[TBL] [Abstract][Full Text] [Related]
11. Implementing continuous quality improvement strategies for improving iron replacement in hemodialysis patients.
Trenkle JA
Nephrol Nurs J; 2001 Oct; 28(5):561-5. PubMed ID: 12143432
[TBL] [Abstract][Full Text] [Related]
12. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of iron dextran for the treatment of iron deficiency in hemodialysis patients.
Fishbane S; Lynn RI
Clin Nephrol; 1995 Oct; 44(4):238-40. PubMed ID: 8575123
[TBL] [Abstract][Full Text] [Related]
14. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
[TBL] [Abstract][Full Text] [Related]
15. Management of anemia in chronic kidney disease (predialysis) patients: nephrology nursing implications.
Wish JB; Weigel KA
Nephrol Nurs J; 2001 Jun; 28(3):341-5. PubMed ID: 12143456
[TBL] [Abstract][Full Text] [Related]
16. A study of parenteral iron regimens in hemodialysis patients.
Besarab A; Kaiser JW; Frinak S
Am J Kidney Dis; 1999 Jul; 34(1):21-8. PubMed ID: 10401011
[TBL] [Abstract][Full Text] [Related]
17. Intravenous iron in chronic kidney disease: haemoglobin change shortly after treatment of patients neither on dialysis nor on erythropoietin.
Tagboto S; Cropper L; Mostafa S; Turner J; Bailey G; Pugh-Clarke K
J Ren Care; 2008 Sep; 34(3):112-5. PubMed ID: 18786076
[TBL] [Abstract][Full Text] [Related]
18. Anemia management protocols: providing consistent hemoglobin outcomes.
Michael M
Nephrol Nurs J; 2005; 32(4):423-6. PubMed ID: 16180783
[TBL] [Abstract][Full Text] [Related]
19. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
El-Khatib M; Duncan HJ; Kant KS
Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness of low-dose maintenance i.v. iron therapy: a dialysis facility's experience.
Peter J; Finkelstein F
Nephrol Nurs J; 2006; 33(1):71-4, 90. PubMed ID: 16538930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
